Wallack M K, Michaelides M
Surgery. 1984 Oct;96(4):791-800.
Specific active tumor immunotherapy methods offer the possibility of increasing the immunogenicity of tumor cells. One of these methods is viral oncolysis, in which tumor cells are modified by viral infection. We prepared vaccinia melanoma oncolysates (VMO) from human melanoma lines infected with vaccinia virus. In a preliminary trial at Washington University, sera from 12 patients with melanoma with stage I and II disease were obtained before and during treatment with VMO. The reactivity of these sera to melanoma lines was examined with a Staphylococcus protein A assay that detects most human IgGs. Our data demonstrate that, during treatment with VMO, sera from all 12 patients developed reactivity to melanoma lines. Selected sera were also tested in a double blind study by the C3-mixed hemadsorption assay, which detects mostly IgM. Results from this assay were in complete agreement with those obtained by the Staphylococcus protein A assay: Pretreatment sera were generally negative and sera obtained during treatment were positive. The specificity of these responses is presently under investigation. Our findings indicate that, as a consequence of treatment with VMO, a reactivity develops in the patients' sera. This reactivity is probably due to both IgG and IgM antibodies and its directed toward antigens expressed on human melanoma lines.
特定的主动肿瘤免疫疗法提供了增强肿瘤细胞免疫原性的可能性。其中一种方法是病毒溶瘤，即通过病毒感染对肿瘤细胞进行改造。我们从感染痘苗病毒的人黑色素瘤细胞系制备了痘苗黑色素瘤溶瘤产物（VMO）。在华盛顿大学的一项初步试验中，收集了12例I期和II期黑色素瘤患者在接受VMO治疗前和治疗期间的血清。使用能检测大多数人IgG的葡萄球菌蛋白A检测法检测这些血清对黑色素瘤细胞系的反应性。我们的数据表明，在VMO治疗期间，所有12例患者的血清都产生了对黑色素瘤细胞系的反应性。在一项双盲研究中，还使用C3混合血细胞吸附检测法对选定的血清进行了检测，该检测法主要检测IgM。该检测结果与葡萄球菌蛋白A检测法的结果完全一致：治疗前血清通常为阴性，治疗期间获得的血清为阳性。目前正在研究这些反应的特异性。我们的研究结果表明，由于VMO治疗，患者血清中产生了反应性。这种反应性可能是由于IgG和IgM抗体共同作用，且其针对的是人类黑色素瘤细胞系上表达的抗原。
